To include your compound in the COVID-19 Resource Center, submit it here.

ATX-MS-1467: Phase I data

An open-label, international Phase I trial in 43 patients with relapsing MS showed that 5 dose levels of intradermal

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE